BR112013002814A2 - uso de composição á base de salvia miltiorrhiza na preparação de drogas para a prevenção secundária de doença cárdiocoronariana - Google Patents

uso de composição á base de salvia miltiorrhiza na preparação de drogas para a prevenção secundária de doença cárdiocoronariana

Info

Publication number
BR112013002814A2
BR112013002814A2 BR112013002814-9A BR112013002814A BR112013002814A2 BR 112013002814 A2 BR112013002814 A2 BR 112013002814A2 BR 112013002814 A BR112013002814 A BR 112013002814A BR 112013002814 A2 BR112013002814 A2 BR 112013002814A2
Authority
BR
Brazil
Prior art keywords
salvia miltiorrhiza
secondary prevention
heart disease
based composition
drug preparation
Prior art date
Application number
BR112013002814-9A
Other languages
English (en)
Other versions
BR112013002814B1 (pt
Inventor
Yan Xijun
Wu Naifeng
YAN Kaijing
Yan He
Guo Zhixin
Zhu Guoguang
Liu Weiwei
Zhao Libin
Luo Ruizhi
Original Assignee
Tasly Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tasly Pharmaceutical Group Co., Ltd. filed Critical Tasly Pharmaceutical Group Co., Ltd.
Publication of BR112013002814A2 publication Critical patent/BR112013002814A2/pt
Publication of BR112013002814B1 publication Critical patent/BR112013002814B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de composição á base de salvia miltiorrhiza na preparação de drogas para a prevenção secundária de doença cárdiocoronariana. é proporcionado o uso de uma composição de salvia miltiorrhiza na preparação de medicamentos para a prevenção secundária de doença cárdiocoronariana, e particularmente o uso da composição de salvia militiorrhiza na preparação de medicamentos para a prevenção secundária de doença cárdiocoronariana do tipo angina pectoris estável e a redução de eventos vasculares graves.
BR112013002814-9A 2010-08-06 2011-08-08 uso de uma composição à base de salvia miltiorrhiza para a prevenção secundária de doença cárdiocoronariana BR112013002814B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010253344 2010-08-06
CN201010253344.5 2010-08-06
PCT/CN2011/078128 WO2012016549A1 (zh) 2010-08-06 2011-08-08 丹参组合物在制备用于冠心病二级预防的药物中的用途

Publications (2)

Publication Number Publication Date
BR112013002814A2 true BR112013002814A2 (pt) 2018-02-06
BR112013002814B1 BR112013002814B1 (pt) 2020-10-27

Family

ID=45558949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002814-9A BR112013002814B1 (pt) 2010-08-06 2011-08-08 uso de uma composição à base de salvia miltiorrhiza para a prevenção secundária de doença cárdiocoronariana

Country Status (17)

Country Link
US (1) US9072745B2 (pt)
EP (1) EP2601958B1 (pt)
JP (2) JP6030556B2 (pt)
KR (2) KR20150107902A (pt)
CN (1) CN103068398B (pt)
AU (1) AU2011288044B8 (pt)
BR (1) BR112013002814B1 (pt)
CA (1) CA2807283C (pt)
DK (1) DK2601958T3 (pt)
EA (1) EA025307B1 (pt)
ES (1) ES2624285T3 (pt)
HK (1) HK1175994A1 (pt)
MX (1) MX353834B (pt)
MY (1) MY160768A (pt)
NZ (1) NZ606595A (pt)
SG (1) SG187715A1 (pt)
WO (1) WO2012016549A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110025830A1 (en) 2009-07-31 2011-02-03 3Dmedia Corporation Methods, systems, and computer-readable storage media for generating stereoscopic content via depth map creation
WO2011014419A1 (en) 2009-07-31 2011-02-03 3Dmedia Corporation Methods, systems, and computer-readable storage media for creating three-dimensional (3d) images of a scene
EA025307B1 (ru) * 2010-08-06 2016-12-30 Тасли Фармасьютикал Груп Ко., Лтд. Применение медицинской композиции в приготовлении лекарственного средства для вторичной профилактики ишемической болезни сердца (ибс) у пациентов с диагнозом стенокардия ii или iii степени по классификации канадского кардиоваскулярного общества
US8274552B2 (en) 2010-12-27 2012-09-25 3Dmedia Corporation Primary and auxiliary image capture devices for image processing and related methods
JP6906307B2 (ja) * 2013-07-11 2021-07-21 タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． 漢方薬組成物、及びそれらの製剤及び用途
AU2014289765B2 (en) * 2013-07-11 2019-05-09 Tasly Pharmaceutical Group Co., Ltd. Preparation method for traditional Chinese medicine micro drop pill and traditional Chinese medicine micro drop pill prepared by using the method
AU2014289766B2 (en) 2013-07-11 2019-03-14 Tasly Pharmaceutical Group Co., Ltd. Traditional chinese medicine composition, and preparation and application thereof
CN104418744B (zh) 2013-08-29 2017-03-01 天士力制药集团股份有限公司 一种新的丹酚酸化合物t、其制备方法和用途
CN104435525A (zh) * 2014-09-01 2015-03-25 周风华 防治细菌性心内膜炎的中药组合物及其制备方法
CN104800520A (zh) * 2015-04-16 2015-07-29 刘瑜 治疗心、小肠病症的红色中药包
CN104840900A (zh) * 2015-06-08 2015-08-19 刘云平 一种治疗心悸的中药
JP6520510B2 (ja) * 2015-07-15 2019-05-29 富士ゼロックス株式会社 情報処理装置及び情報処理プログラム
CN104998216A (zh) * 2015-08-19 2015-10-28 鄢明亮 一种用于预防治疗心悸的中药袋泡茶及制备方法
CN107137665B (zh) * 2017-06-02 2020-11-24 烟台大学 一种防治心肌纤维化的中药组合物及其应用
CN107714857A (zh) * 2017-12-01 2018-02-23 王章琳 一种治疗心脑血管病的中药组合物及其制备方法
KR102127706B1 (ko) * 2018-08-29 2020-06-29 윤화순 복합 한방 생약 추출물을 포함하는 혈행 개선용 제제
KR102127726B1 (ko) * 2018-08-29 2020-06-29 윤화순 복합 한방 생약 추출물을 포함하는 혈행 개선용 제제
CN111297942A (zh) * 2019-12-23 2020-06-19 卓和药业集团有限公司 一种治疗心肌缺血的复方制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
KR100374416B1 (ko) * 2000-11-14 2003-03-04 노용일 고지혈증 및 협심증 예방 및 치료용 생약조성물
CN1161140C (zh) * 2001-11-09 2004-08-11 天津天士力制药股份有限公司 一种预防和治疗冠心病心绞痛的药物及其制备方法和其它用途
EP1351698B1 (en) * 2000-12-22 2013-01-23 Tasly Pharmaceutical Group Co., Ltd. Herbal composition for angina pectoris, method to prepare same and uses thereof
US8486464B2 (en) * 2000-12-22 2013-07-16 Tasly Pharmaceutical Group Co. Ltd. Herbal composition for angina pectoris, method to prepare same and uses thereof
CN1202103C (zh) * 2002-05-23 2005-05-18 天津天士力制药股份有限公司 丹参总酚酸的制备方法
CN100339085C (zh) 2003-09-23 2007-09-26 天津天士力制药股份有限公司 治疗心脑血管疾病的中药组合物
CN100450501C (zh) * 2004-03-17 2009-01-14 天津天士力制药股份有限公司 一种治疗心脑血管疾病的中药制剂及其制备方法
CN100404041C (zh) * 2004-06-30 2008-07-23 天津天士力制药股份有限公司 一种治疗冠心病的药物组合物
CN1785249B (zh) 2004-12-06 2011-03-23 天津天士力制药股份有限公司 一种含有丹参的药物组合物的新用途
CN1919248B (zh) * 2005-08-24 2011-04-27 天津天士力制药股份有限公司 一种治疗心脑血管病的中药制剂
EA025307B1 (ru) * 2010-08-06 2016-12-30 Тасли Фармасьютикал Груп Ко., Лтд. Применение медицинской композиции в приготовлении лекарственного средства для вторичной профилактики ишемической болезни сердца (ибс) у пациентов с диагнозом стенокардия ii или iii степени по классификации канадского кардиоваскулярного общества

Also Published As

Publication number Publication date
CN103068398A (zh) 2013-04-24
KR20130073938A (ko) 2013-07-03
HK1175994A1 (en) 2013-07-19
CN103068398B (zh) 2015-08-19
AU2011288044B2 (en) 2014-07-17
BR112013002814B1 (pt) 2020-10-27
MX2013001298A (es) 2013-03-08
JP2016183201A (ja) 2016-10-20
AU2011288044B8 (en) 2014-08-07
US20130196005A1 (en) 2013-08-01
EP2601958B1 (en) 2017-03-29
CA2807283C (en) 2019-05-14
MX353834B (es) 2018-01-31
EA201300159A8 (ru) 2014-11-28
SG187715A1 (en) 2013-03-28
AU2011288044A8 (en) 2014-08-07
KR20150107902A (ko) 2015-09-23
ES2624285T3 (es) 2017-07-13
DK2601958T3 (en) 2017-07-17
MY160768A (en) 2017-03-15
JP2013533292A (ja) 2013-08-22
EP2601958A4 (en) 2013-12-18
CA2807283A1 (en) 2012-02-09
EA201300159A1 (ru) 2013-11-29
EP2601958A1 (en) 2013-06-12
EA025307B1 (ru) 2016-12-30
JP6030556B2 (ja) 2016-11-24
AU2011288044A1 (en) 2013-02-21
US9072745B2 (en) 2015-07-07
WO2012016549A1 (zh) 2012-02-09
NZ606595A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
BR112013002814A2 (pt) uso de composição á base de salvia miltiorrhiza na preparação de drogas para a prevenção secundária de doença cárdiocoronariana
EA201400172A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
CY1118263T1 (el) Φλουρμπιπροφαινη ελεγχομενης εκλυσης και μυοχαλαρωτικοι συνδιασμοι
JP2012517449A5 (pt)
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
GT200500266A (es) Nuevos derivados de pirimidina y su uso
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
SMT201500048B (it) Composizione farmaceutica con attivita'antimicrobica e cicatrizzante per somministrazione esterna e procedimento per la preparazione della stessa
BRPI0418764B8 (pt) uso de espinosina, ou de um derivado ou sal fisiologicamente aceitável da mesma, na preparação de medicamentos para promover ou acelerar a cura de ferimento em um ser humano
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
BR112012018135A2 (pt) preparação farmacêutica, e, método para fabricar a preparação farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2011, OBSERVADAS AS CONDICOES LEGAIS.